Serum amylase level as a predictive biomarker for persistent grade 1 chemotherapy-associated oral mucositis: a retrospective cross-sectional study.

IF 2.4 3区医学 Q3 ONCOLOGY

International Journal of Clinical Oncology Pub Date : 2025-04-03 DOI:10.1007/s10147-025-02749-7

Nursema Ozdemir, Ali Alkan, Ozgur Tanriverdi

{"title":"Serum amylase level as a predictive biomarker for persistent grade 1 chemotherapy-associated oral mucositis: a retrospective cross-sectional study.","authors":"Nursema Ozdemir, Ali Alkan, Ozgur Tanriverdi","doi":"10.1007/s10147-025-02749-7","DOIUrl":null,"url":null,"abstract":"Background: This study aims to determine the relationship between persistent grade 1 chemotherapy-related oral mucositis and serum amylase level.Methods: The study was conducted as a retrospective cross-sectional study. Among the patients diagnosed with cancer whose file information was available, the files of those whose chemotherapy-related oral mucositis status was recorded after the first cycle treatment were examined. Among these patients, those whose serum amylase levels were checked for any reason and those who did not meet the exclusion criteria were included in the study.Results: A total of 376 patients were analyzed. It was observed that grade 1 oral mucositis persisted in 44% of the patients. With the ROC curve, the cut-off value for serum amylase level before the second cycle treatment was determined to be 69.5 U/L (AUC 0.771, 95% CI 0.720-0.821, p = 0.00011). The sensitivity rate of serum amylase levels above this value in predicting chemotherapy-associated oral mucositis was 68.29% and the specificity rate was 100%. In univariate and multivariate logistic (binary) regression analysis, it was concluded that high serum amylase level was an independent factor affecting the presence of oral mucositis (OR 3.37, 95% CI 1.94-9.66; p = 0.00014).Conclusion: It was concluded that serum amylase level may be an independent predictive factor for determining persistent grade 1 chemotherapy-induced oral mucositis. Original.","PeriodicalId":13869,"journal":{"name":"International Journal of Clinical Oncology","volume":" ","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s10147-025-02749-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: This study aims to determine the relationship between persistent grade 1 chemotherapy-related oral mucositis and serum amylase level.

Methods: The study was conducted as a retrospective cross-sectional study. Among the patients diagnosed with cancer whose file information was available, the files of those whose chemotherapy-related oral mucositis status was recorded after the first cycle treatment were examined. Among these patients, those whose serum amylase levels were checked for any reason and those who did not meet the exclusion criteria were included in the study.

Results: A total of 376 patients were analyzed. It was observed that grade 1 oral mucositis persisted in 44% of the patients. With the ROC curve, the cut-off value for serum amylase level before the second cycle treatment was determined to be 69.5 U/L (AUC 0.771, 95% CI 0.720-0.821, p = 0.00011). The sensitivity rate of serum amylase levels above this value in predicting chemotherapy-associated oral mucositis was 68.29% and the specificity rate was 100%. In univariate and multivariate logistic (binary) regression analysis, it was concluded that high serum amylase level was an independent factor affecting the presence of oral mucositis (OR 3.37, 95% CI 1.94-9.66; p = 0.00014).

Conclusion: It was concluded that serum amylase level may be an independent predictive factor for determining persistent grade 1 chemotherapy-induced oral mucositis. Original.

查看原文本刊更多论文

血清淀粉酶水平作为持续1级化疗相关口腔黏膜炎的预测性生物标志物：一项回顾性横断面研究

背景：本研究旨在确定持续1级化疗相关性口腔黏膜炎与血清淀粉酶水平的关系。方法：采用回顾性横断面研究。在可获得档案资料的癌症诊断患者中，检查第一周期治疗后记录化疗相关口腔黏膜炎状况的患者档案。在这些患者中，因任何原因检查血清淀粉酶水平的患者和不符合排除标准的患者被纳入研究。结果：共分析376例患者。观察到44%的患者持续存在1级口腔黏膜炎。通过ROC曲线确定第二周期治疗前血清淀粉酶水平的临界值为69.5 U/L （AUC 0.771, 95% CI 0.720 ~ 0.821, p = 0.00011）。血清淀粉酶水平高于该值对预测化疗相关口腔黏膜炎的敏感性为68.29%，特异性为100%。单因素和多因素logistic回归分析表明，血清淀粉酶水平高是影响口腔黏膜炎存在的独立因素(OR 3.37, 95% CI 1.94-9.66；P = 0.00014)。结论：血清淀粉酶水平可能是判断持续1级化疗所致口腔黏膜炎的独立预测因素。原创。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Clinical Oncology 医学-肿瘤学

CiteScore

6.80

自引率

3.00%

发文量

175

审稿时长

2 months

期刊介绍： The International Journal of Clinical Oncology (IJCO) welcomes original research papers on all aspects of clinical oncology that report the results of novel and timely investigations. Reports on clinical trials are encouraged. Experimental studies will also be accepted if they have obvious relevance to clinical oncology. Membership in the Japan Society of Clinical Oncology is not a prerequisite for submission to the journal. Papers are received on the understanding that: their contents have not been published in whole or in part elsewhere; that they are subject to peer review by at least two referees and the Editors, and to editorial revision of the language and contents; and that the Editors are responsible for their acceptance, rejection, and order of publication.